alpha-aminopyridine has been researched along with Urinary Bladder Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, RJ; Chang, SC; Chen, YT; Chiu, YL; Dong, JR; Hsu, CH; Hsu, FS; Huang, KH; Kuo, KL; Liao, SM; Lin, WC; Liu, SH; Yang, SP | 1 |
| Chang, YC; Chen, SL; Sung, WW; Wang, SC; Wu, YC; Yu, CY | 1 |
| Chang, HC; Chang, YW; Chow, PM; Hsu, CH; Huang, KH; Kuo, KL; Liao, SM; Lin, WC; Liu, SH; Shi, CS; Yang, SP | 1 |
| Bode-Lesniewska, B; Fritz, C; John, H; Pless, M; Reinhart, S; Trachsel, Y; Wagner, U | 1 |
| Azimova, B; Chen, WH; Jiang, PZ; Liu, WL; Njoya, EM; Peng, T; Qiang, Z; Shi, N; Wang, F; Zhang, GL; Zhou, ZY | 1 |
| Chu, X; Dai, Y; Hao, Z; Yi, Y; Yuxin, T; Zheng, X; Zhou, Y | 1 |
| Beijersbergen, RL; Bernards, R; Halonen, P; Leite de Oliveira, R; Lieftink, C; Šuštić, T; van de Ven, M; van den Heuvel, MM; van der Heijden, MS; Wang, L | 1 |
| Barker, HE; Dillon, MT; Hafsi, H; Harrington, K; Khoo, V; Kyula, J; McLaughlin, M; Patel, R; Schick, U; Thompson, A; Zaidi, S | 1 |
| Chakraborty, TK; Filshie, RJ; Lee, MR | 1 |
9 other study(ies) available for alpha-aminopyridine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Humans; Mice, Nude; Thiocyanates; Ubiquitin Thiolesterase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Topics: Administration, Intravesical; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; BCG Vaccine; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Mitomycin; Neoplasm Recurrence, Local; Rats; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Deubiquitinating Enzymes; Enzyme Inhibitors; Humans; Immunohistochemistry; Mice; Proto-Oncogene Proteins c-bcl-2; Thiocyanates; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; Cystoscopy; Female; Fibronectins; Gene Fusion; Humans; Inflammation; Lactams; Myofibroblasts; Neoplasms, Muscle Tissue; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.
Topics: Aminopyridines; Animals; Antiviral Agents; Benzamides; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclooxygenase 2; Cyclopropanes; Disease Models, Animal; Drug Synergism; Enzyme Activation; Female; HEK293 Cells; Humans; Interferon-alpha; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins; Urinary Bladder Neoplasms | 2018 |
MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen-activated protein kinase pathway.
Topics: Acetamides; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Purines; Receptor, Adenosine A2B; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2019 |
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice, Nude; Molecular Targeted Therapy; Morpholines; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Receptors, Fibroblast Growth Factor; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2017 |
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Topics: Administration, Oral; Aminopyridines; Animals; Cell Line, Tumor; Checkpoint Kinase 1; Female; G2 Phase Cell Cycle Checkpoints; Head and Neck Neoplasms; Histones; Humans; Mice; Pyrimidines; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2017 |
Methaemoglobinaemia produced by phenazopyridine (Pyridium) in a man with chronic obstructive airways disease.
Topics: Aged; Aminopyridines; Carcinoma in Situ; Humans; Lung Diseases, Obstructive; Male; Methemoglobinemia; Phenazopyridine; Urinary Bladder Neoplasms | 1987 |